title: Should we be using activated protein C to treat severe sepsis?
authors.affiliation: Anaesthesia and Intensive Care Medicine, Department of Intensive Care, Derriford Hospital, Plymouth, Devon, UK.
authors.forename: R L
authors.initials: RL
authors.lastname: Eve
authors.forename: M R
authors.initials: MR
authors.lastname: Duffy
mesh_terms: D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015337:Multicenter Studies as Topic; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D000890:Anti-Infective Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated